Johnson & Johnson (JNJ) said it’s exploring ways to resume making the cancer medicine Doxil by September after a production shutdown at a supplier last year contributed to a shortage. Boehringer Ingelheim GmbH (BING)’s Ben Venue Laboratories factory in Ohio stopped production in November after regulators questioned the product quality. Ben Venue said it may resume operations by the end of 2012. J&J plans to transfer the manufacturing to another supplier, said Lisa Vaga, a spokeswoman for the New Brunswick, New Jersey-based company.
